Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

cell cancer

- PMLiVE

BMS shares positive three-year results for Sotyktu in plaque psoriasis

Up to 100 million people worldwide are affected by some form of the immune-mediated disease

- PMLiVE

BMS shares positive long-term data for Zeposia in relapsing multiple sclerosis

Approximately 2.5 million people worldwide are affected by the neurological disease

- PMLiVE

Bristol Myers Squibb to acquire Mirati Therapeutics for up to $5.8bn

The transaction would mark a significant boost to the US drugmaker’s oncology portfolio

- PMLiVE

Merck shares positive results for Keytruda in phase 3 bladder cancer study

Over 82,000 people in the US will be be diagnosed with bladder cancer in 2023

- PMLiVE

Bristol Myers Squibb reveals plans to double number of drugs in registrational trials

The drugmaker expects to expand its research pipeline from six to 12 over next 18 months

- PMLiVE

BMS presents positive six-year results for Opdivo/Yervoy combination in lung cancer

NSCLC is the most common type of lung cancer, representing up to 85% of diagnoses

- PMLiVE

IO Biotech announces new data supporting its therapeutic cancer vaccine

The vaccine showed promise when used in combination with Merck & Co’s Keytruda

- PMLiVE

Bristol Myers Squibb’s Camzyos recommended by NICE for inherited heart condition

One in 500 people in the UK are affected by hypertrophic cardiomyopathy

- PMLiVE

BMS pays Zenas $50m upfront for regional rights to autoimmune disease antibody

The company will gain exclusive rights to develop and commercialise obexelimab

- PMLiVE

Merck receives EC approval for Keytruda combination in gastric cancer

Over one million new cases of gastric cancer were diagnosed globally in 2020

- PMLiVE

Bristol Myers Squibb’s Opdivo approved by EC for expanded melanoma use

The global incidence of skin cancer has been rising steadily over the past few decades

- PMLiVE

Merck shares positive late-stage results for Welireg in advanced kidney cancer

Renal cell carcinoma accounts for approximately 90% of kidney cancer diagnoses

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links